Exact Sciences (EXAS) Earnings Call Presentation

Financial Performance & Growth - Exact Sciences reported total revenue of $2.76 billion in 2024, a 10% year-over-year increase[7] - Adjusted EBITDA for 2024 was $323 million, up 48% year-over-year[7] - The company anticipates total revenue between $3.07 billion and $3.12 billion in 2025, representing a 12% increase at the midpoint[47] - Screening revenue in 2024 was $2.104 billion and is projected to be between $2.39 billion and $2.425 billion in 2025, a 14% increase at the midpoint[20, 47] - Precision Oncology revenue in 2024 was $655 million and is projected to be between $680 million and $695 million in 2025, a 5% increase at the midpoint[29, 47] - The company is targeting approximately 15% compounded annual revenue growth from 2022-2027 and over 20% adjusted EBITDA margin in 2027[50, 52] Product Development & Market Opportunity - Exact Sciences is launching three new advanced cancer tests in 2025: Oncodetect for molecular residual disease ($18 billion TAM), Cancerguard for multi-cancer screening ($25 billion TAM), and Cologuard Plus for colon cancer screening ($15 billion TAM)[4, 5] - Cologuard has saved the U S healthcare system $22 billion[16] - Cancerguard could reduce cancer mortality by 17%[41]